CN103874491A - 喷他脒-偕胺肟酸酯作为前药以及其作为药物的用途 - Google Patents
喷他脒-偕胺肟酸酯作为前药以及其作为药物的用途 Download PDFInfo
- Publication number
- CN103874491A CN103874491A CN201280037041.7A CN201280037041A CN103874491A CN 103874491 A CN103874491 A CN 103874491A CN 201280037041 A CN201280037041 A CN 201280037041A CN 103874491 A CN103874491 A CN 103874491A
- Authority
- CN
- China
- Prior art keywords
- pentamidine
- compound
- prodrug
- bis
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 23
- 229940079593 drug Drugs 0.000 title claims description 6
- 229940002612 prodrug Drugs 0.000 title abstract description 72
- 239000000651 prodrug Substances 0.000 title abstract description 72
- 239000002253 acid Substances 0.000 title description 3
- 150000002148 esters Chemical class 0.000 title description 2
- UREYBSXWRHBDHQ-UHFFFAOYSA-N 4-[5-[4-(n'-hydroxycarbamimidoyl)phenoxy]pentoxy]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(\N)=N\O)C=C1 UREYBSXWRHBDHQ-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims abstract description 14
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims abstract description 14
- 201000000317 pneumocystosis Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 208000004554 Leishmaniasis Diseases 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 201000004792 malaria Diseases 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 208000000230 African Trypanosomiasis Diseases 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 241000223105 Trypanosoma brucei Species 0.000 claims description 7
- 208000029080 human African trypanosomiasis Diseases 0.000 claims description 7
- 201000002612 sleeping sickness Diseases 0.000 claims description 7
- 210000002784 stomach Anatomy 0.000 claims description 7
- 150000008064 anhydrides Chemical class 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 231100000956 nontoxicity Toxicity 0.000 claims description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical class C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 abstract description 142
- 201000002311 trypanosomiasis Diseases 0.000 abstract 1
- 229960004448 pentamidine Drugs 0.000 description 112
- 125000004423 acyloxy group Chemical group 0.000 description 36
- 210000000056 organ Anatomy 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 210000002381 plasma Anatomy 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 238000011534 incubation Methods 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 238000001994 activation Methods 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108090000371 Esterases Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 0 *C(*C(O*=C(*)c1ccc(*2*C2)cc1)=*)O Chemical compound *C(*C(O*=C(*)c1ccc(*2*C2)cc1)=*)O 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 108010051152 Carboxylesterase Proteins 0.000 description 4
- 102000013392 Carboxylesterase Human genes 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000282894 Sus scrofa domesticus Species 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 150000001409 amidines Chemical group 0.000 description 3
- 229960003328 benzoyl peroxide Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000001768 subcellular fraction Anatomy 0.000 description 3
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical class O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 3
- -1 succinyl pentamidine Chemical compound 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000798443 Hornodermoporus martius Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108010051357 endoexonuclease Proteins 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11175252.3A EP2550963B1 (de) | 2011-07-25 | 2011-07-25 | Pentamidin-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel |
| EP11175252.3 | 2011-07-25 | ||
| PCT/EP2012/064171 WO2013014059A1 (de) | 2011-07-25 | 2012-07-19 | Pentamidin-amidoximsäureesters als prodrugs und ihre verwendung als arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103874491A true CN103874491A (zh) | 2014-06-18 |
Family
ID=46514404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280037041.7A Pending CN103874491A (zh) | 2011-07-25 | 2012-07-19 | 喷他脒-偕胺肟酸酯作为前药以及其作为药物的用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20130085180A1 (enExample) |
| EP (1) | EP2550963B1 (enExample) |
| JP (2) | JP2014529579A (enExample) |
| KR (1) | KR20140097108A (enExample) |
| CN (1) | CN103874491A (enExample) |
| AU (1) | AU2012288968B2 (enExample) |
| BR (1) | BR112014001787A2 (enExample) |
| CA (1) | CA2842355A1 (enExample) |
| DK (1) | DK2550963T3 (enExample) |
| ES (1) | ES2610652T3 (enExample) |
| HR (1) | HRP20170013T1 (enExample) |
| HU (1) | HUE030245T2 (enExample) |
| LT (1) | LT2550963T (enExample) |
| PL (1) | PL2550963T3 (enExample) |
| PT (1) | PT2550963T (enExample) |
| RS (1) | RS55557B1 (enExample) |
| RU (1) | RU2608388C2 (enExample) |
| SI (1) | SI2550963T1 (enExample) |
| WO (1) | WO2013014059A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150126595A (ko) | 2012-12-21 | 2015-11-12 | 벌릭스 파마 인코포레이티드 | 간 질환 또는 증상의 치료를 위한 용도 및 방법 |
| WO2019067696A1 (en) * | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS FOR INHIBITING STAT3 |
| US10835581B2 (en) | 2017-11-28 | 2020-11-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Method of treating insulin resistance |
| CA3124412A1 (en) * | 2018-12-20 | 2020-06-25 | Auransa Inc. | Analogues of pentamidine and uses therefor |
| WO2024211870A2 (en) * | 2023-04-07 | 2024-10-10 | Auransa Inc. | Pentamidine analogue polymorphs, formulations, and methods thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786383A (en) * | 1993-06-28 | 1998-07-28 | Clement; Bernd | Pharmaceutical preparation |
| US20110028756A1 (en) * | 2008-02-01 | 2011-02-03 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723495A (en) * | 1995-11-16 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Benzamidoxime prodrugs as antipneumocystic agents |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
-
2011
- 2011-07-25 SI SI201131053A patent/SI2550963T1/sl unknown
- 2011-07-25 RS RS20170002A patent/RS55557B1/sr unknown
- 2011-07-25 HU HUE11175252A patent/HUE030245T2/en unknown
- 2011-07-25 LT LTEP11175252.3T patent/LT2550963T/lt unknown
- 2011-07-25 ES ES11175252.3T patent/ES2610652T3/es active Active
- 2011-07-25 EP EP11175252.3A patent/EP2550963B1/de not_active Not-in-force
- 2011-07-25 DK DK11175252.3T patent/DK2550963T3/en active
- 2011-07-25 PT PT111752523T patent/PT2550963T/pt unknown
- 2011-07-25 PL PL11175252T patent/PL2550963T3/pl unknown
-
2012
- 2012-07-19 CN CN201280037041.7A patent/CN103874491A/zh active Pending
- 2012-07-19 BR BR112014001787A patent/BR112014001787A2/pt not_active IP Right Cessation
- 2012-07-19 AU AU2012288968A patent/AU2012288968B2/en not_active Ceased
- 2012-07-19 WO PCT/EP2012/064171 patent/WO2013014059A1/de not_active Ceased
- 2012-07-19 KR KR1020147004770A patent/KR20140097108A/ko not_active Withdrawn
- 2012-07-19 JP JP2014522041A patent/JP2014529579A/ja not_active Withdrawn
- 2012-07-19 CA CA2842355A patent/CA2842355A1/en not_active Abandoned
- 2012-07-19 RU RU2014106867A patent/RU2608388C2/ru not_active IP Right Cessation
- 2012-10-05 US US13/554,536 patent/US20130085180A1/en not_active Abandoned
-
2016
- 2016-09-06 JP JP2016173855A patent/JP2017039727A/ja not_active Withdrawn
-
2017
- 2017-01-05 HR HRP20170013TT patent/HRP20170013T1/hr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786383A (en) * | 1993-06-28 | 1998-07-28 | Clement; Bernd | Pharmaceutical preparation |
| US20110028756A1 (en) * | 2008-02-01 | 2011-02-03 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012288968A1 (en) | 2014-02-13 |
| RU2608388C2 (ru) | 2017-01-18 |
| JP2017039727A (ja) | 2017-02-23 |
| DK2550963T3 (en) | 2017-01-30 |
| CA2842355A1 (en) | 2013-01-31 |
| WO2013014059A1 (de) | 2013-01-31 |
| EP2550963B1 (de) | 2016-10-12 |
| JP2014529579A (ja) | 2014-11-13 |
| AU2012288968B2 (en) | 2017-01-05 |
| KR20140097108A (ko) | 2014-08-06 |
| HRP20170013T1 (hr) | 2017-03-10 |
| BR112014001787A2 (pt) | 2017-02-21 |
| RS55557B1 (sr) | 2017-05-31 |
| HUE030245T2 (en) | 2017-04-28 |
| LT2550963T (lt) | 2017-02-27 |
| PL2550963T3 (pl) | 2017-08-31 |
| SI2550963T1 (sl) | 2017-05-31 |
| US20130085180A1 (en) | 2013-04-04 |
| RU2014106867A (ru) | 2015-08-27 |
| EP2550963A1 (de) | 2013-01-30 |
| ES2610652T3 (es) | 2017-04-28 |
| PT2550963T (pt) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10513539B2 (en) | Hydrophobic modified peptides and their use for liver specific targeting | |
| CN103874491A (zh) | 喷他脒-偕胺肟酸酯作为前药以及其作为药物的用途 | |
| JP2017530961A (ja) | Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法 | |
| CN113604214A (zh) | 一种高稳定性溶瘤肽荧光探针及其制备方法和应用 | |
| CN103945845A (zh) | 作为前药的达比加群-偕胺肟酸酯及其作为药物的用途 | |
| JP2023530272A (ja) | 急性肺障害の治療におけるｃ型ナトリウム利尿ペプチド及びその方法 | |
| JP5918538B2 (ja) | 医薬の生物活性を改善するための方法 | |
| KR102686264B1 (ko) | 소세포폐암 치료용 치아우라닙 | |
| US9662308B2 (en) | Orally bioavailable pentamidine prodrugs for the treatment of diseases | |
| TW202513043A (zh) | 丹磺醯胺修飾的psma靶向化合物及其製備方法和應用 | |
| RU2427373C1 (ru) | Средство для индукции эндогенного интерферона | |
| US20220194930A1 (en) | Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same | |
| Fan et al. | Examination of charge modifications of an endolysosomal trapping inhibitor in an antagonistic NTSR1-targeted construct for colon cancer | |
| AU2013226944B2 (en) | Inhibitory agent for body cavity fluid accumulation | |
| WO2023123008A1 (zh) | 一种双胍衍生物及其应用 | |
| CN107586321B (zh) | F-18标记修饰Dimer-San A探针的制备方法 | |
| CN120518782A (zh) | 一种分支型双靶点融合多肽及其应用 | |
| CN119367338A (zh) | 天然产物苏木查尔酮作为成纤维细胞激活蛋白抑制剂的应用 | |
| CN120757475A (zh) | 一种靶向slc25a1的小分子抑制剂ctp13及其应用 | |
| CN107709324A (zh) | 黄嘌呤衍生物 | |
| WO2025092956A1 (zh) | 用于靶向性降解骨硬化蛋白的适体缀合物 | |
| CN118146292A (zh) | 靶向fap的小分子化合物及其制备方法与应用 | |
| CN120518783A (zh) | 一种双靶点融合蛋白及其应用 | |
| CN120529905A (zh) | 抗病毒药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140618 |